Free tool
FAERS Monitor: Ritalin La
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021284 or its brand name (Ritalin La, Methylphenidate Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
15,239
Serious
10,224
67% of reports
Hospitalization
3,632
Death reported
1,114
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,483
- off label use912
- fatigue776
- nausea727
- anxiety722
- toxicity to various agents687
- headache673
- depression576
- somnolence503
- insomnia500
- condition aggravated497
- dizziness483
- vomiting459
- product substitution issue433
- drug abuse415
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 10 |
| 2005 | 26 |
| 2006 | 12 |
| 2007 | 6 |
| 2008 | 5 |
| 2009 | 19 |
| 2010 | 165 |
| 2011 | 233 |
| 2012 | 302 |
| 2013 | 425 |
| 2014 | 423 |
| 2015 | 749 |
| 2016 | 1,521 |
| 2017 | 1,106 |
| 2018 | 1,030 |
| 2019 | 1,055 |
| 2020 | 914 |
| 2021 | 868 |
| 2022 | 1,089 |
| 2023 | 1,340 |
| 2024 | 1,368 |
| 2025 | 1,416 |
| 2026 | 1,157 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,038,920 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product substitution issueSignal | 433 | 10.5 | 9.5 | 3,674 |
| drug abuseSignal | 415 | 6.9 | 6.3 | 2,090 |
| toxicity to various agentsSignal | 687 | 5.6 | 5.2 | 2,629 |
| anxietySignal | 722 | 3.5 | 3.3 | 1,306 |
| depressionSignal | 576 | 3.5 | 3.2 | 1,035 |
| somnolenceSignal | 503 | 3.5 | 3.2 | 881 |
| insomniaSignal | 500 | 2.6 | 2.4 | 493 |
| condition aggravatedSignal | 497 | 2.3 | 2.1 | 352 |
| drug ineffective | 1,483 | 1.6 | 1.5 | 311 |
| headache | 673 | 1.5 | 1.4 | 108 |
| off label use | 912 | 1.4 | 1.4 | 126 |
| fatigue | 776 | 1.4 | 1.3 | 82 |
| vomiting | 459 | 1.3 | 1.2 | 42 |
| dizziness | 483 | 1.3 | 1.2 | 42 |
| nausea | 727 | 1.3 | 1.2 | 42 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.